期刊
CURRENT PHARMACEUTICAL DESIGN
卷 27, 期 20, 页码 2366-2380出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612826666200811175513
关键词
Chidamide; TRAIL; apoptosis; drug resistance; breast cancer; HDACi
资金
- Natural Science Foundation of China [81172509, 81502188]
- Innovative Talents Support Foundation for Liaoning Universities of Department of Education of Liaoning Province [LR2017040]
- Research Foundation of Science and Technology Department of Liaoning Province [2018010621301, 2018225016, 2017012046301, 2015020251]
- Research Foundation of Shenyang Science and Technology Bureau [18013088]
The combination of Chidamide and TRAIL has been shown to effectively induce breast cancer cell death while reducing the concentration of Chidamide. Additionally, the combination treatment also inhibits breast cancer tumor growth and is correlated with the expression of related apoptosis and autophagy factors.
Background: Breast cancer is one of the most prevalent diseases threatening women's health today. Indepth research on breast cancer (BC) pathogenesis and prevention and treatment methods are gradually receiving attention. Chidamide is a novel histone deacetylase inhibitor (HDACi) that depresses the function of histone deacetylase, consequently affecting the growth of BC cells through epigenetic modification. However, preclinical and clinical studies show that chidamide is ineffective in long-term treatment. We demonstrated in previous experiments that TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in BC cells and is significantly less non-toxic to normal cells than chidamide. Therefore, in this study, we treated BC cells with chidamide and TRAIL to explore a novel option to reduce the clinical toxicity through augmenting the sensitivity for BC cells. Methods and Results: Results from the MTT and cell viability assays indicated that the combination of chidamide and TRAIL in MCF-7 and MDA-MB-231 cells induced BC cell death, while maintaining a reduced concentration of chidamide. Autophagy assay and annexin V analysis showed that the autophagosome microtubuleassociated protein1light chain3-II (LC3-II) was abnormally increased and much more early and late phase of apoptotic cells appeared during chidamide and TRAIL induction. Anti-tumor assays in a BC tumor xenograft model displayed that the mixture of chidamide and TRAIL exhibited stronger effects on inhibiting tumor growth. The data from real-time PCR and western blotting showed that the cytotoxic effect correlated with the expressions of related apoptosis and autophagy factors. Conclusion: Our data are the first to demonstrate the synergistic effects of chidamide and TRAIL in BC cells, specifically, the pharmacological effects on cell death induction. These results lay a solid experimental and theoretical basis to solve the clinical resistance of chidamide.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据